259 related articles for article (PubMed ID: 18320935)
1. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
Ly JK; Margot NA; MacArthur HL; Hung M; Miller MD; White KL
Antivir Chem Chemother; 2007; 18(6):307-16. PubMed ID: 18320935
[TBL] [Abstract][Full Text] [Related]
2. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.
White KL; Margot NA; Ly JK; Chen JM; Ray AS; Pavelko M; Wang R; McDermott M; Swaminathan S; Miller MD
AIDS; 2005 Nov; 19(16):1751-60. PubMed ID: 16227782
[TBL] [Abstract][Full Text] [Related]
3. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.
White KL; Chen JM; Feng JY; Margot NA; Ly JK; Ray AS; Macarthur HL; McDermott MJ; Swaminathan S; Miller MD
Antivir Ther; 2006; 11(2):155-63. PubMed ID: 16640096
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
White KL; Margot NA; Wrin T; Petropoulos CJ; Miller MD; Naeger LK
Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
[TBL] [Abstract][Full Text] [Related]
5. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
7. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
White KL; Chen JM; Margot NA; Wrin T; Petropoulos CJ; Naeger LK; Swaminathan S; Miller MD
Antimicrob Agents Chemother; 2004 Mar; 48(3):992-1003. PubMed ID: 14982794
[TBL] [Abstract][Full Text] [Related]
9. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance.
Xu HT; Martinez-Cajas JL; Ntemgwa ML; Coutsinos D; Frankel FA; Brenner BG; Wainberg MA
Retrovirology; 2009 Feb; 6():14. PubMed ID: 19210791
[TBL] [Abstract][Full Text] [Related]
10. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Parikh UM; Zelina S; Sluis-Cremer N; Mellors JW
AIDS; 2007 Jul; 21(11):1405-14. PubMed ID: 17589186
[TBL] [Abstract][Full Text] [Related]
12. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Andreatta KN; Goodman DD; Miller MD; White KL
Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
[TBL] [Abstract][Full Text] [Related]
13. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
15. Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.
Álvarez M; Nevot M; Mendieta J; Martínez MA; Menéndez-Arias L
J Biol Chem; 2018 Feb; 293(7):2247-2259. PubMed ID: 29275329
[TBL] [Abstract][Full Text] [Related]
16. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
Andreatta KN; Miller MD; White KL
Antimicrob Agents Chemother; 2016 Feb; 60(2):757-65. PubMed ID: 26574015
[TBL] [Abstract][Full Text] [Related]
17. K65R, TAMs and tenofovir.
Miller MD
AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
[TBL] [Abstract][Full Text] [Related]
18. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
19. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
García-Lerma JG; MacInnes H; Bennett D; Reid P; Nidtha S; Weinstock H; Kaplan JE; Heneine W
J Virol; 2003 May; 77(10):5685-93. PubMed ID: 12719561
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
